Heparanase expression by Barrett's epithelium and during esophageal carcinoma progression

Modern Pathology

Volumn 22, Issue 12, 2009, Pages 1548-1554

  Brun, Rita ^a   Naroditsky, Inna ^a   Waterman, Matti ^a   Ben Izhak, Ofer ^a   Groisman, Gabriel ^b   Ilan, Neta ^c   Vlodavsky, Israel ^c  

^a Rambam Health Care Campus ^*  (Israel)

^b HILLEL YAFFE MEDICAL CENTER   (Israel)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Adenocarcinoma; Barrett's epithelium; Esophageal; Heparanase; Localization; Staining

Indexed keywords

HEPARAN SULFATE; HEPARANASE;

ARTICLE; BARRETT ESOPHAGUS; BASEMENT MEMBRANE; CANCER SURVIVAL; CORRELATION ANALYSIS; DYSPLASIA; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME REGULATION; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS MUCOSA; EXTRACELLULAR MATRIX; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS; METASTASIS POTENTIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOCARCINOMA; BARRETT ESOPHAGUS; CELL PROLIFERATION; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; GLUCURONIDASE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; PRECANCEROUS CONDITIONS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 71149093505     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2009.115     Document Type: Article

References (43)

1. Parish CR, Freeman C, Hulett MD. Heparanase: a key enzyme involved in cell invasion. Biochim Biophys Acta 2001;1471:M99-108.
2. Vlodavsky I, Friedmann Y. Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J Clin Invest 2001;108:341-347. (Pubitemid 32730777)
3. Bishop JR, Schuksz M, Esko JD. Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature 2007;446:1030-1037.
4. Iozzo RV. Basement membrane proteoglycans: from cellar to ceiling. Nat Rev Mol Cell Biol 2005;6:646-656.
5. Edovitsky E, Elkin M, Zcharia E, et al. Heparanase gene silencing, tumor invasiveness, angiogenesis, and metastasis. J Natl Cancer Inst 2004;96:1219-1230.
6. Edovitsky E, Lerner I, Zcharia E, et al. Role of endothelial heparanase in delayed-type hypersensitiv-ity. Blood 2006;107:3609-3616.
7. Ilan N, Elkin M, Vlodavsky I. Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol 2006;38: 2018-2039. (Pubitemid 44397619)
8. Vreys V, David G. Mammalian heparanase: what is the message? J Cell Mol Med 2007;11:427-452.
9. Ferro V, Hammond E, Fairweather JK. The development of inhibitors of heparanase, a key enzyme involved in tumour metastasis, angiogenesis and inflammation. Mini Rev Med Chem 2004;4:693-702.
10. McKenzie EA. Heparanase: a target for drug discovery in cancer and inflammation. Br J Pharmacol 2007; 151:1-14.
11. Miao HQ, Liu H, Navarro E, et al. Development of heparanase inhibitors for anti-cancer therapy. Curr Med Chem 2006;13:2101-2111.
12. Vlodavsky I, Ilan N, Naggi A, et al. Heparanase: structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate. Curr Pharm Des 2007;13:2057-2073.
13. Chen JQ, Zhan WH, He YL, et al. Expression of heparanase gene, CD44v6, MMP-7 and nm23 protein and their relationship with the invasion and metastasis of gastric carcinomas. World J Gastroenterol 2004;10: 776-782.
14. Doviner V, Maly B, Kaplan V, et al. Spatial and temporal heparanase expression in colon mucosa throughout the adenoma-carcinoma sequence. Mod Pathol 2006;19:878-888.
15. Friedmann Y, Vlodavsky I, Aingorn H, et al. Expression of heparanase in normal, dysplastic, and neoplas-tic human colonic mucosa and stroma. Evidence for its role in colonic tumorigenesis. Am J Pathol 2000;157: 1167-1175.
16. Nobuhisa T, Naomoto Y, Ohkawa T, et al. Heparanase expression correlates with malignant potential in human colon cancer. J Cancer Res Clin Oncol 2005; 131:229-237.
17. Tang W, Nakamura Y, Tsujimoto M, et al. Heparanase: a key enzyme in invasion and metastasis of gastric carcinoma. Mod Pathol 2002;15:593-598.
18. Mikami S, Ohashi K, Katsube K, et al. Coexpression of heparanase, basic fibroblast growth factor and vascular endothelial growth factor in human esophageal carcinomas. Pathol Int 2004;54:556-563.
19. Mikami S, Ohashi K, Usui Y, et al. Loss of syndecan-1 and increased expression of heparanase in invasive eso-phageal carcinomas. Jpn J Cancer Res 2001;92:1062-1073.
20. Ohkawa T, Naomoto Y, Takaoka M, et al. Localization of heparanase in esophageal cancer cells: respective roles in prognosis and differentiation. Lab Invest 2004;84:1289-1304.
21. Okawa T, Naomoto Y, Nobuhisa T, et al. Heparanase is involved in angiogenesis in esophageal cancer through induction of cyclooxygenase-2. Clin Cancer Res 2005;11:7995-8005.
22. Quinlan JM, Colleypriest BJ, Farrant M, et al. Epithelial metaplasia and the development of cancer. Biochim Biophys Acta 2007;1776:10-21.
23. Schuchert MJ, Luketich JD. Barrett's esophagus-emerging concepts and controversies. J Surg Oncol 2007;95:185-189.
24. Odze RD. Diagnosis and grading of dysplasia in Barrett's oesophagus. J Clin Pathol 2006;59:1029-1038.
25. Cohen E, Doweck I, Naroditsky I, et al. Heparanase is overexpressed in lung cancer and correlates inversely with patient survival. Cancer 2008;113:1004-1011.
26. Waterman M, Ben-Izhak O, Eliakim R, et al. Hepar-anase upregulation by colonic epithelium in inflammatory bowel disease. Mod Pathol 2007;20:8-14.
27. Zetser A, Levy-Adam F, Kaplan V, et al. Processing and activation of latent heparanase occurs in lysosomes. J Cell Sci 2004;117:2249-2258.
28. Cohen-Kaplan V, Doweck I, Naroditsky I, et al. Heparanase augments epidermal growth factor receptor phosphorylation: correlation with head and neck tumor progression. Cancer Res 2008;68:10077-10085.
29. Casu B, Vlodavsky I, Sanderson RD. Non-anticoagulant heparins and inhibition of cancer. Pathophysiol Hae-most Thromb 2008;36:195-203.
30. Yang Y, MacLeod V, Dai Y, et al. The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy. Blood 2007;110:2041-2048.
31. Shafat I, Ben-Barak A, Postovsky S, et al. Heparanase levels are elevated in the plasma of pediatric cancer patients and correlate with response to anticancer treatment. Neoplasia 2007;9:909-916.
32. Shafat I, Pode D, Peretz T, et al. Clinical significance of urine heparanase in bladder cancer progression. Neoplasia 2008;10:125-130.
33. Shafat I, Zcharia E, Nisman B, et al. An ELISA method for the detection and quantification of human heparanase. Biochem Biophys Res Commun 2006;341:958-963.
34. Ben-Zaken O, Gingis-Velitski S, Vlodavsky I, et al. Heparanase induces Akt phosphorylation via a lipid raft receptor. Biochem Biophys Res Commun 2007;361:829-834.
35. Cohen-Kaplan V, Naroditsky I, Zetser A, et al. Heparanase induces VEGF C and facilitates tumor lymphangiogenesis. Int J Cancer 2008;123:2566-2573.
36. Fux L, Feibish N, Cohen-Kaplan V, et al. Structure-function approach identifies a C-terminal domain that mediates heparanase signaling. Cancer Res 2009;69: 1758-1767.
37. Gingis-Velitski S, Zetser A, Flugelman MY, et al. Heparanase induces endothelial cell migration via protein kinase B/Akt activation. J Biol Chem 2004; 2004:279:23536-279:23541.
38. Nadir Y, Brenner B, Zetser A, et al. Heparanase induces tissue factor expression in vascular endothelial and cancer cells. J Thromb Haemost 2006;4:2443-2451.
39. Zetser A, Bashenko Y, Edovitsky E, et al. Heparanase induces vascular endothelial growth factor expression: correlation with p38 phosphorylation levels and Src activation. Cancer Res 2006;66:1455-1463.
40. Schubert SY, Ilan N, Shushy M, et al. Human heparanase nuclear localization and enzymatic activity. Lab Invest 2004;84:535-544.
41. Takaoka M, Naomoto Y, Ohkawa T, et al. Heparanase expression correlates with invasion and poor prognosis in gastric cancers. Lab Invest 2003;83: 613-622.
42. Doweck I, Kaplan-Cohen V, Naroditsky I, et al. Heparanase localization and expression by head and neck cancer: correlation with tumor progression and patient survival. Neoplasia 2006;8:1055-1061.
43. Kobayashi M, Naomoto Y, Nobuhisa T, et al. Hepar-anase regulates esophageal keratinocyte differentiation through nuclear translocation and heparan sulfate cleavage. Differentiation 2006;74:235-243.